XVIVO Perfusion Competitors and Similar CompaniesClear all
XVIVO Perfusion's competitors and similar companies include Eyenovia and Emulate.
 XVIVO Perfusion XVIVO Perfusion is a medical technology company that develops machines and perfusion solutions. |  Eyenovia Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. | ||
Founding Date | Founding Date 1998 | Founding Date 2014 | Founding Date 2014 |
Type | Type Public | Type Public | Type Private |
Tags | |||
Locations | Locations Mölndal, SE HQ Shanghai, CN Novegro Tregarezzo, IT Groningen, NL Lund, SE Mölndal, SE Aurora, US see more | Locations New York, US HQ | Locations Boston, US HQ |
Employees | Employees 19320% increase | Employees 22100% increase | Employees 802% decrease |
Valuation ($) | Valuation ($) 1.4 b | Valuation ($) 47.3 m | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) kr812.2m (FY, 2025) | Revenue (est.) $813.5k (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods kr208.5m (FY, 2025) | Cost of goods $303.3k (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit kr605.4m (FY, 2025) | Gross profit $510.2k (FY, 2025) | Gross profit N/A |
Net income | Net income kr25.2m (FY, 2025) | Net income ($45.3m) (FY, 2025) | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
Eyenovia
HQ
New York, US
Employees
22
Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform.
View company
Emulate
HQ
Boston, US
Employees
80↓ 2% decrease
Emulate is a biotechnology company that specializes in organ-on-chips technology.
View company